These findings corroborate favorable preliminary clinical experience reported by others and indicate that cotrimoxazole deserves further study in the therapy of bacterial meningitis.
Haemophilus influenzae type b is the most common cause of bacterial meningitis in early childhood and an occasional but increasingly frequent cause of this disease in older children and adults (15) . Mortality ranges from 2 to 10% (21) , and survivors may suffer from permanent neurological sequelae (29) .
Clinical isolates of H. influenzae type b were uniformly susceptible to ampicillin until 1974, when cases of meningitis caused by ampicillinresistant H. influenzae type b were fint recognized (7, 9, 30) . Because ,-lactamase-producing strains presently account for 5 to 18% of the cases of H. influenzae type b meningitis and bacteremia in the United States (8) , most clinicians now routinely include chloramphenicol in their initial treatment of children with bacterial meningitis (1) . This therapeutic approach generally has proved successful. Ampicillin and chloramphenicol have additive or even synergistic activity against many strains ofH. influenzae type b (12) . However, it should be noted that for pneumococci this combination may be antagonistic, both in vitro and in experimental aniimals (13, 31) . Mathies et al. (25) reported that clinical outcome of bacterial meningitis was somewhat worse in patients treated with combined ampicillin, chloramphenicol, and streptomycin than in patients treated with ampicillin alone. Other potential disadvantages of combining ampicillin and chloramphenicol include chloramphenicol toxicity, the occasional occurrence of chloramphenicol-resistant strains (17, 23) , and the recent observation that both ampicillin and chloramphenicol resistance may occur simultaneously and be transnissible from one strain of H. influenzae to another (5) .
These considerations encouraged us to study altemative regimens for treatment of bacterial meningitis. Here (6) , and the Table 3 shows the mean reduction in the (26, 27) . Both trimethoprim and sulfamethoxazole reach relatively high levels in human CSF (10, 14, 19) . The combination is relatively nontoxic, and extensive clinical experience has proven its efficacy in treatment of other bacterial infections in both children and adults. For these reasons, cotrimoxazole has already been used for treatment of meningitis in several uncontrolled case studies (3, 11, 16, 20, 28) . Results were encouraging. LaFaix et al. (20) reported treatment of 844 patients with bacterial meningitis with cotrimox. azole, ampicillin, or a combination of penicillin, chloramphenicol, and sulfonamide. Clinical outcome in the 108 patients treated with cotrimoxazole was comparable to results achieved by the other regimens. Sabel and Brandberg (28) reported recovery in nine of ten patients with meningitis and septicemia who were treated with cotrimoxazole after they had failed to improve on conventional antibiotic therapy. Thus, considerable uncontrolled clinical experience has already accumulated, indicating that cotrimoxazole is effective in treatment of central nervous system infections.
Despite such experience cotrimoxazole has been little used for treatment of meningitis in the United States. This is presumably because a parenteral preparation is not generally available, and because treatment with conventional antimicrobial regimens is reasonably successful, at least for the common pathogens. However, if ampicillin and chloramphenicol resistance among H. influenzae type b and penicillin resistance among S. pneumoniae becomes more prevalent or if Neisseria meningitidis, like N. gonorrhoeae, were to develop penicillin resistance, the present satisfactory situation could change. These are potential problems in future management of meningitis due to the three most common pathogens, but treatment of gram-negative bacillary meningitis is far from satisfactory even now. With conventional antibiotic therapy, mortality and long-term morbidity are higher in gram-negative bacillary meningitis than in other forms of meningitis (24) 4, 1977) . Cotrimoxazole is of potential value in this setting. It has activity against many species of gramnegative bacilli (other than Pseudomonas), and its mechanism of action at separate stages of bacterial metabolism may confer some protection against the emergence of resistant strains. These considerations led us to anticipate increasing interest in cotrimoxazole for the therapy of bacterial meningitis and encouraged us to examine the efficacy of this drug in an experimental model. In rabbits injected intracisternally with H. influenzae type b, both trimethoprim and sulfamethoxazole reached high concentrations in CSF in a ratio favorable for antimicrobial synergy. These CSF levels inhibited both the ,Blactamase-negative and f8-lactamase-positive strains of H. influenzae type b with equal efficacy. Cotrimoxazole was as effective as ampicillin in meningitis due to the ampicillin-sensitive strain, and as effective as chloramphenicol in /i-lactamase-positive H. influenzae type b meningitis. Thus, in vivo efficacy of cotrimoxazole, ampicillin, and chloramphenicol correlated with the MICs and the CSF penetration of these antimicrobial agents.
It is of particular interest that trimethoprim plus sulfamethoxazole, unlike ampicillin and chloramphenicol, was not bactenrcidal for either of our strains of H. influenzae type b in vitro. Kirven and Thornsberry (18) 
